tiprankstipranks
Advertisement
Advertisement
Alnylam presents new data on vutrisiran in ATTR-CM at ACC.26
PremiumThe FlyAlnylam presents new data on vutrisiran in ATTR-CM at ACC.26
28d ago
Alnylam presents new data on potential of zilebesiran for hypertension
Premium
The Fly
Alnylam presents new data on potential of zilebesiran for hypertension
28d ago
Alnylam Pharmaceuticals: Solid TTR Demand but Near‑Term Headwinds Justify Hold Rating
Premium
Ratings
Alnylam Pharmaceuticals: Solid TTR Demand but Near‑Term Headwinds Justify Hold Rating
28d ago
Alnylam: Strong Amvuttra Outperformance and High-Value Pipeline Optionality Support Buy Rating
PremiumRatingsAlnylam: Strong Amvuttra Outperformance and High-Value Pipeline Optionality Support Buy Rating
2M ago
Alnylam price target raised to $429 from $415 at Canaccord
Premium
The Fly
Alnylam price target raised to $429 from $415 at Canaccord
2M ago
Alnylam price target raised to $429 from $415 at Canaccord
Premium
The Fly
Alnylam price target raised to $429 from $415 at Canaccord
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100